Utility of recombinant enzyme kinetics in prediction of human clearance: Impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates

Drug Metabolism and Disposition

Volumn 32, Issue 12, 2004, Pages 1411-1420

  Galetin, Aleksandra ^a   Brown, Caroline ^a   Hallifax, David ^a   Ito, Kiyomi ^b   Houston, J Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CYTOCHROME P450 2C19; CYTOCHROME P450 3A5; DIAZEPAM; FLUNITRAZEPAM; MIDAZOLAM; RECOMBINANT ENZYME; TEMAZEPAM; TRIAZOLAM;

ARTICLE; CELL VIABILITY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME KINETICS; HUMAN; HUMAN TISSUE; HYDROXYLATION; INDIVIDUALIZATION; LIVER MICROSOME; MONTE CARLO METHOD; PREDICTION; PRIORITY JOURNAL; SIMULATION; UTILIZATION REVIEW; VIRUS EXPRESSION;

ALGORITHMS; ARYL HYDROCARBON HYDROXYLASES; BENZODIAZEPINES; BIOTRANSFORMATION; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; RECOMBINANT PROTEINS;

UNIDENTIFIED BACULOVIRUS;

EID: 9444270510     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.000844     Document Type: Article

References (39)

1. Andersson T, Miners JO, Veronese ME, and Birkett DJ (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 38:131-137.
2. Armitage P, Berry G, and Matthews JNS (2002) Analysing non-normal data, in Statistical Methods in Medical Research, 4th ed, pp 272-311. Blackwell Science, Washington, DC.
3. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, and Villén T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45:348-355.
4. Crespi CL (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:180-235.
5. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, and Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595-606.
6. Foti RS and Fisher MB (2003) Characterization of cytochrome P450 3A4 and 3A5 leveles in a human liver microsome bank using midazolam and paclitaxel metabolic activity and immunoquantitation. Drug Metab Rev 35 (Suppl 2):34.
7. Gorski JC, Hall SD, Jones DR, Vandenbranden M, and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
8. Gorski JC, Jones DR, Hamman MA, Wrighton SA, and Hall SD (1999) Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica 29:931-944.
9. Galetin A, Clarke SE, and Houston JB (2003) Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone and nifedipine. Drug Metab Dispos 31:1108-1116.
10. Hesse LM, Venkatakrishnan K, von Moltke LL, Shade RI, and Greenblatt DJ (2001) CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos 29:133:140.
11. Hirota N, Ito K, Iwatsubo T, Green CE, Tyson CA, Shimada N, Suzuki H, and Sugiyama Y (2001) In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm Drug Dispos 22:53-71.
12. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
13. Houston JB, Kenworthy KE, and Galetin A (2003) Typical and atypical enzyme kinetics, in Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development (Fisher M, Lee J, and Obach S, eds) pp 211-254, Font Media, Lausanne.
14. Huang W, Lin YS, Dai Y, Totah RA, Calamia JC, and Thummel KE (2003) Comparative drug metabolism by CYP3A4 and CYP3A5. Drug Metab Rev 35 (Suppl 2):187.
15. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klatti J, Eiselt R, et al. (2001) The genetic determinants of CYP3A5 polymorphism. Pharmacogenetics 11:773-779.
16. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, and Sugiyama Y (1998) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461-499.
17. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Dal A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A4 promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
18. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Delivery Rev 54:1271-1294.
19. Lin YS, Dowling ALS, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal metabolism of midazolam. Mol Pharmacol 62:162-172.
20. Lin YS, Lockwood GF, Graham MA, Brian WR, Loi C-M, Dobrinska MR, Shen DD, Watkins PB, Wilkinson OR, Kharasch ED, and Thummel KE (2001) In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11:781-791.
21. Nakajima M, Tane K, Nakamura S, Shimada N, Yamazaki H, and Yokoi T (2002) Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b5 in the expression system and the differences in the marker activities. J Pharm Sci 91:952-963.
22. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Edrenyi L, and Kashuba AD (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388.
23. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
24. Patki KC, von Moltke LL, and Greenblatt DJ (2003) In vitro metabolism of midazolam, triazolam, nifedipine and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab Dispos 31:938-944.
25. Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2004) Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151-178.
26. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping. Biochem Pharmacol 57:465-480.
27. Segel IH (1975) Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steady State Enzyme Systems. John Wiley & Sons Inc, New York.
28. Shih P-S and Huang J-D (2002) Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 30:1491-1496.
29. Störmer E, von Moltke LL, and Greenblatt DJ (2000) Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. J Pharmacol Exp Ther 295:793-801.
30. Thummel KE (2003) Does the CYP3A*3 polymorphism affect in vivo drug elimination? Pharmacogenetics 13:585-587.
31. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
32. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblat DJ (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504.
33. Voice MW, Zhang Y, Wolf CR, Burchell B, and Friedberg T (1999) Effects of human cytochrome b5 on CYP3A4 activity and stability in vivo. Arch Biochem Biophys 366:116-124.
34. Wedlund PJ (2000) The CYP2C19 enzyme polymorphism. Pharmacology 61:174-183.
35. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761.
36. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5 and CYP3A7. Drug Metab Dispos 30:883-891.
37. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, and Gurney H (2004) CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 14:471-478.
38. Xie H-G, Wood AJJ, Kim RB, Stein CM, and Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.
39. Yamazaki H, Nakano M, Imai Y, Ueng Y-F, Guengerich FP, and Shimada T (1996) Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch Biochem Biophys 325:174-182.